Incyte Corp (NASDAQ:INCY)
| 77.69 Delayed Data As of Jul 01 |  +1.72 / +2.26%Today’s Change | 61.91 Today|||52-Week Range 84.86 | +5.84% Year-to-Date |
Latest INCY News | Press Releases
| 3 Bargain Stocks Near 52-Week Lows to Buy and Forget Jun 29 / StockNews.com - Paid Partner Content | 3 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget Jun 26 / MotleyFool.com - Paid Partner Content |
| 5 High-Performing Cathie Wood Stocks as of June Jun 28 / GuruFocus News - Paid Partner Content | Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion Jun 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 75.97 |
| Today’s open | 75.45 |
| Day’s range | 75.43 - 77.86 |
| Volume | 83,853 |
| Average volume (3 months) | 1,432,055 |
| Market cap | $17.2B |
Data as of 3:59pm ET, 07/01/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -50.37% |
| Earnings growth (next 5 years) | +25.46% |
| Revenue growth (last year) | +11.98% |
| P/E ratio | 18.5 |
| Price/Sales | 5.46 |
| Price/Book | 4.55 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALNYAlnylam Pharmaceutic... | +2.42 | +1.66% |
| HZNPHorizon Therapeutics... | +1.07 | +1.34% |
| CTLTCatalent Inc | -0.31 | -0.29% |
| VTRSViatris Inc | +0.23 | +2.24% |
Data as of 4:00pm ET, 07/01/2022
Financials
| Next reporting date | August 2, 2022 |
| EPS forecast (this quarter) | $0.54 |
| Annual revenue (last year) | $3.0B |
| Annual profit (last year) | $948.6M |
| Net profit margin | 31.76% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
